RxDoctor Payments Data

Jennifer Hunke

Medical · Lexington, NENPI 1104197433

Payments from drug & device makers

$822in general payments, 2019–2025

Across 50 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$265
  • AbbVie$139
  • Astellas Pharma US Inc$111
  • Pfizer$45
  • Abiomed$39
  • Exact Sciences$32
  • plus $191 from 11 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$822 in reported general payments places this provider in the 60th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$86,622
Medicare patients
225
Services billed
10,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$50,141
FarxigaDapagliflozin Propanediol58$33,918
EliquisApixaban51$28,653
TrulicityDulaglutide21$21,320
Bydureon BciseExenatide Microspheres21$18,821
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,723
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$12,535
XareltoRivaroxaban19$11,262
LinzessLinaclotide12$6,043
ArexvyRsvpref3 Antigen/As01e/Pf12$3,802
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,894
Atorvastatin Calcium191$2,760
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,305
Duloxetine Hcl55$1,803
Levothyroxine Sodium143$1,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$265$50,14149 claims
PfizerEliquis$45$28,65351 claims
Johnson & JohnsonXarelto$19$11,26219 claims
AbbVieLinzess$139$6,04312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 216 medical providers in Nebraska.

Other medical in Lexington

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →